



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/40, 31/415, 31/421, 31/426, 31/496, 31/506, 31/4164, 31/5377, C07D 207/30, 231/10, 233/54, 403/00, 413/00	A1	(11) International Publication Number: WO 00/57877 (43) International Publication Date: 5 October 2000 (05.10.00)
(21) International Application Number: PCT/US00/07944 (22) International Filing Date: 24 March 2000 (24.03.00) (30) Priority Data: 60/126,553 26 March 1999 (26.03.99) US (71) Applicant (for all designated States except US): COCENSYS, INC. [US/US]; 213 Technology Drive, Irvine, CA 92618 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): HOGENKAMP, Derk, J. [US/US]; 4510 Park Drive, Carlsbad, CA 92008 (US). UPASANI, Ravindra [IN/US]; 63 Montecilo, Rothill Ranch, CA 92610 (US). NGUYEN, Phong [US/US]; 1048 Wingfoot Street, Placentia, CA 92870 (US). (74) Agents: COVERT, John, M.; Sterne, Kessler, Goldstein & Fox P.L.L.C., Suite 600, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US) et al.		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE (Utility model), DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(54) Title: ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF		
(I)		
(57) Abstract This invention relates to compounds having Formula (I) or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Het and R₅-R₁₃ are set in the specification. The invention also is directed to the use of compounds of Formula (I) for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.		